GenSight to price initial sale of 4.65 million ADS at $13.00 to $15.00

Bookrunners Leerink Partners, Evercore and Canaccord Genuity assist

By Devika Patel

Knoxville, Tenn., Oct. 27 – GenSight Biologics SA will sell 4.65 million American Depositary Shares in its initial public offering with a 30-day greenshoe of 697,500 additional ADS, according to a Form F-1/A filed Tuesday with the Securities and Exchange Commission.

The ADS, which represent a total of 4.65 million ordinary shares, will be sold at a price expected to fall between $13.00 and $15.00 apiece.

Leerink Partners, Evercore ISI and Canaccord Genuity are the bookrunners.

Proceeds will be used for preclinical and clinical development, research and development, working capital, capital expenditures and other general corporate purposes.

The biotechnology company is based in Paris. The company intends to list its ADSs on the Nasdaq under the symbol “GNST.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.